Abstract
Acquired haemophilia A (AHA) is a rare bleeding disorder resulting from autoimmune reactionagainst factor VIII, which may occur in patients with viral infections. Treatment withrecombinant porcine factor VIII has been proven to be effective amongst patients with AHA.Its effectiveness is enhanced by the possibility of adjusting the dosage to the peak and troughlevels of factor VIII.We present here a case report of a patient who developed AHA three months afterSars-Cov-2 infection. He was the one of the first persons in Poland to be treated with rpFVIII.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
